Video

Immune Checkpoint Inhibitors in NSCLC

For High-Definition, Click

The substantial benefits derived from treatment with immune checkpoint inhibitors could have the most meaningful impact in non-small cell lung cancer (NSCLC), believes Louis M. Weiner, MD. Effective treatments are desperately needed for this type of cancer, as the death rate from this disease is among the highest in the world.

The PD-1 and PD-L1 inhibitors have consistently demonstrated responses in the 20% to 25% range, notes Mark A. Socinski, MD. However, the duration is the most impressive aspect of these responses, as they tend to be long lasting.

The median age of patients with NSCLC is 71 with the existence of comorbidities, which places further importance on toxicity, notes Socinski. Without phase III data, it is difficult to compare the efficacy and toxicity between PD-1 and PD-L1-targeted agents in NSCLC, notes Roy S. Herbst, MD. However, targeting PD-L1 directly rather than PD-1 leaves PD-L2 intact. This prevents some side effects, such as colitis and pneumonitis, Herbst notes.

Biomarker analyses for patient selection remain unclear for these agents, Herbst notes. Trials have selected patients based on PD-L1 status with varying results. Responses are higher in PD-L1-positive patients; however, those with PD-L1-negative disease still respond to therapy.

Traditionally, the most effective approaches involve the combination of several therapies. However, combination strategies could be more difficult to find in NSCLC, since the population is older with more comorbidity, Herbst notes. For some patients (20% to 25%), the immune checkpoint inhibitor alone seems sufficient, Weiner notes. At this point, finding the patients who require further treatment remains an unmet need.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity